Quarterly report [Sections 13 or 15(d)]

Stockholders??? Equity (Tables)

v3.26.1
Stockholders’ Equity (Tables)
 3 Months Ended
Mar. 31, 2026
Stockholders’ Equity [Abstract]  
Schedule of Warrant and Stock Option Grants with Time-Based Vesting

The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the three months ended March 31, 2026 were:

 

    Warrant Grants     Stock Option Grants     Restricted
Stock
Units		  
    Number of
shares
subject to
warrants		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
options		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
restricted
stock units		  
Balance at December 31, 2025     3,603,677     $ 4.77           -     $        -       8,147  
Granted     -       -       -       -       -  
Exercised     (3,334 )     4.65       -       -       -  
Cancelled/Expired     (402 )     900.00       -       -       -  
Balance at March 31, 2026     3,599,941     $ 4.67       -     $ -       8,147  
Exercisable at March 31, 2026     2,335,535     $ 4.67       -     $ -       8,147  

 

 

The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the three months ended March 31, 2025 were:

 

    Warrant Grants     Stock Option Grants     Restricted
Stock
Units		  
    Number of
shares
subject to
warrants		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
options		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
restricted
stock units		  
Balance at December 31, 2024     594,387     $ 13.80            -     $       -       8,147  
Granted     483,758       20.10       -       -       -  
Exercised     -       -       -       -       -  
Cancelled/Expired     -       -       -       -       -  
Balance at March 31, 2025     1,078,145     $ 16.65       -     $ -       8,147  
Exercisable at March 31, 2025     1,078,145     $ 16.65       -     $ -       8,147  
Schedule of Company’s Outstanding Warrants

The Company’s outstanding warrants at March 31, 2026 are as follows:

 

Warrants Outstanding   Warrants Exercisable
Exercise Price Range   Number Outstanding     Weighted Average Remaining Contractual Life 
(in years)		     Weighted Average Exercise Price     Number Exercisable   Weighted Average Exercise Price     Intrinsic
Value		  
$4.65 - $7.92     3,599,941       3.55     $ 4.67     2,335,535   $ 4.67     $    -  

 

The Company’s outstanding warrants at March 31, 2025, are as follows:

 

Warrants Outstanding     Warrants Exercisable  
Exercise Price
Range		     Number
Outstanding		     Weighted Average
Remaining
Contractual Life
(in years)		     Weighted
Average
Exercise Price		     Number
Exercisable		     Weighted
Average
Exercise Price		     Intrinsic
Value		  
  $12.90 - $900.00       1,078,145       4.53     $ 16.65       1,078,145     $ 16.65       2,792,060  
Schedule of Stock-based Compensation Expense

As of March 31, 2026 and December 31, 2025, there was no unrecognized expense for unvested stock options and restricted stock awards.

 

    For the Three Months Ended  
    March 31,  
    2026     2025  
Stock-based compensation expense   $ 12,404     $ -  

 

Stock-based compensation expense categorized by the equity components for the three months ended March 31, 2026 and 2025 is as follows:

 

    For the Three Months Ended  
    March 31,  
    2026     2025  
Common stock   $ 12,404     $ -  
Total   $ 12,404     $ -